XLO
Xilio Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.00
−0.22%Year over year
Reported trailing growth
- Revenue
- +327.3%
- EBITDA
- +63.3%
- EBIT
- +44.6%
- EPS
- +88.3%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -75.5%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +589.9%
- EBITDA
- +42.3%
- EBIT
- +30.7%
- Net income
- +39.8%
- EPS
- +72.5%
- Free cash flow
- +70.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026